CAR-T Cell Therapy — Reprogramming Your Own Cells

CAR-T cell therapy uses your own immune cells as the treatment. T cells are collected from your blood, reprogrammed in a laboratory to carry a new receptor, grown into a dose, and infused back. That receptor lets them recognise one specific protein on the cancer cell. One infusion is the whole course.

CAR-T stands for chimeric antigen receptor T cell. A T cell is an immune cell that already hunts abnormal cells. The chimeric antigen receptor is an added lock-and-key protein, built into the cell by inserting a gene. It gives the T cell a target it would not otherwise see reliably.

This matters for a practical reason. Checkpoint-inhibitor immunotherapy is a drug that takes the brakes off immune cells you already have. CAR-T is not a drug at all. It is a living product made from one patient, for that one patient, and it cannot be given to anyone else.

Said plainly, before anything else: CION Cancer Clinics does not provide CAR-T cell therapy or any other cell therapy. We do not administer it, stock it or manufacture it. This page exists so you can understand what you have read about, and so we can point you to the right specialist centre if your diagnosis is one where CAR-T is genuinely discussed.

1. 1

   Your cells are collected

   Blood passes through a machine that separates out the T cells and returns the rest to you. This is called leukapheresis. It takes a few hours and needs no surgery.

2. 2

   The cells travel, frozen and tracked

   The collection is cryopreserved and shipped to a licensed manufacturing site. A chain-of-identity label follows the batch in both directions, because these cells belong to one named person.

3. 3

   A gene is inserted

   A viral vector delivers the gene that makes your T cells display the chimeric antigen receptor. This is the reprogramming step. Nothing from another person is added to the cells.

4. 4

   The batch is grown

   The modified cells are multiplied over several days until there are enough for a dose. Most of the waiting time families experience sits in this step and the one after it.

5. 5

   Release testing

   Sterility, identity, potency and viability are all checked before the batch can be released. A batch that fails cannot be swapped for another one. The process restarts from collection.

6. 6

   Lymphodepleting chemotherapy, then the infusion

   A short chemotherapy course a few days before infusion makes room for the new cells to expand. The infusion itself usually takes under an hour.

7. 7

   Weeks of monitoring near the centre

   Patients stay at or close to the treating centre afterwards. The reactions that need urgent treatment mostly appear in the first two weeks, so distance from the hospital is part of the plan.

Categories follow NCCN and ESMO patient-education frameworks. Whether any of them applies to you depends on your exact diagnosis, prior treatment and fitness — only your treating haemato-oncologist can answer that.

On published figures, list prices reported internationally for approved CAR-T products have sat in the region of several crore rupees for the infusion alone, before hospital and monitoring costs. India’s domestically developed CAR-T therapy was reported at a small fraction of that when it launched, which changed the conversation but still leaves it beyond what most families can self-fund. Treat both as indicative, as of August 2026: they come from published manufacturer and news reports, not from a CION rate card. CION does not provide CAR-T and quotes no price for it. If cost is your real question, ask the treating centre for a written estimate that separates the product, the hospital stay and the monitoring.

• Cytokine release syndrome — a whole-body inflammatory reaction as the cells activate. Typically starts within the first week. Managed with specific medicines kept ready at the treating centre.
• Neurological effects (ICANS) — confusion, difficulty finding words, tremor or, less often, seizures. Typically starts within the first two weeks and is usually reversible with treatment.
• Low blood counts and infection risk — counts can stay low for weeks or months after infusion, and loss of normal B cells may mean immunoglobulin support for a period.
• Not everyone reaches the infusion — disease can progress during the manufacturing wait, or a batch can fail release testing. Both are real outcomes worth asking the centre about in advance.
• Long-term follow-up is compulsory — regulators require years of follow-up after gene-modified cell therapy, because long-term data on these products is still maturing. Nobody should tell you otherwise.

Response to CAR-T varies widely by disease, by prior treatment and by individual. Guideline bodies including NCCN and ESMO describe meaningful responses in a proportion of patients with relapsed or refractory disease, and are equally clear that it does not work for everyone. Ask the treating centre for the realistic picture for your specific case, in writing.

No. CION Cancer Clinics does not administer, stock or manufacture CAR-T cell therapy or any other cell therapy. If a page, an agent or a forwarded message tells you otherwise, it is wrong.

What we can do is read your reports and tell you whether your diagnosis is even in a category where CAR-T gets discussed, explain what the pathway would involve in practice, and give you a written second opinion on the treatment you have already been offered. Where a referral to an accredited cell-therapy centre is the right next step, we will say so.

The immunotherapy given as day care at CION centres is checkpoint-inhibitor therapy — a different class of treatment with a different mechanism, a different schedule and a different side-effect pattern. Response-assessment PET-CT during that treatment is coordinated at partner imaging centres rather than owned by CION.

• How Immunotherapy Actually Causes Side Effects — the mechanism behind cytokine release and immune-related reactions, explained for the checkpoint-inhibitor treatment most patients are actually offered.
• PD-1 and PD-L1 Inhibitors: What the Difference Is — the class of immunotherapy CION does give as day care, and the one most often confused with CAR-T in news coverage.
• Biosimilars: Are They the Same as the Original Product? — useful if your real question is cost, since biosimilar checkpoint inhibitors are where affordability has actually moved in India.
• Immunotherapy at CION Cancer Clinics — the treatments CION does provide, how eligibility is assessed, and what a first consultation covers.

This page is general information and does not replace a consultation. CION Cancer Clinics does not provide CAR-T or cell therapy; immunotherapy at CION means checkpoint-inhibitor treatment given as day care, with response-assessment PET-CT coordinated at partner imaging centres. Cost figures are indicative, as of August 2026, and drawn from published reports. Only your treating oncologist, reviewing your complete case, can tell you what applies to you.

Families ask about CAR-T long before it is on the table

If you have read about CAR-T and want to know whether it has anything to do with your diagnosis, ask us. You will get a plain answer, including when the answer is no.